ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Infectious Disease BriefingsThe Journal of Infectious Diseases
Infectious DiseaseClinical Practice3 min read

Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration

We analyzed gut microbiota among 22 virally-suppressed PWH and 12 ECs before and 9-months after randomization to aspirin or atorvastatin.

Published in The Journal of Infectious DiseasesClinical evidence review
3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Source

Follow-Up Window

9-months

These findings suggest that ECs have gut resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut diversity in PWH.

What Changes?

Infectious Disease · Clinical Practice

Current Standard

Conventional infectious disease practice relies on standard-of-care monitoring and existing regimens prior to this clinical evidence review.

New Finding

There was a significant change in beta diversity after aspirin administration, but no difference in after atorvastatin.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    There were no differences in between PWH and EC at baseline.

  2. 02Study Evidence

    Study design used a clinical evidence review protocol to track clinical outcomes.

  3. 03Practical Meaning

    Benefits and risks vary by individual health history — discuss with a healthcare professional.

What This Means for You

There was a significant change in beta diversity after aspirin administration, but no difference in after atorvastatin. These findings suggest that ECs have gut resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut diversity in PWH.

The Discovery

Gut dysbiosis is associated with chronic immune activation in people with HIV (PWH), but is not well-characterized in elite controllers (ECs) or PWH receiving aspirin or . We analyzed gut among 22 virally-suppressed PWH and 12 ECs before and 9-months after randomization to aspirin or atorvastatin. There were no differences in between PWH and EC at baseline.

How It Works, Simply

This infectious disease research focuses on immune response. Researchers evaluated it using a standard-of-care clinical practice · Clinical evidence review at the clinical practice stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    There were no differences in between PWH and EC at baseline.

  2. 02Study Evidence

    Study design used a clinical evidence review protocol to track clinical outcomes.

  3. 03Practical Meaning

    Benefits and risks vary by individual health history — discuss with a healthcare professional.

01

Biological Mechanism & Study Design

Study Design & Cohort

Clinical evidence review

Standard-of-care clinical practice · Clinical evidence review · Clinical Practice

Biological Pathway & Modality

Immune response

Intervention: Evaluation of gut composition in elite controllers and

02

Experimental Findings & Endpoints

Gut dysbiosis is associated with chronic immune activation in people with HIV (PWH), but is not well-characterized in elite controllers (ECs) or PWH receiving aspirin or .

We analyzed gut among 22 virally-suppressed PWH and 12 ECs before and 9-months after randomization to aspirin or atorvastatin. There were no differences in between PWH and EC at baseline.

03

Clinical Translation & Practice Context

There was a significant change in beta diversity after aspirin administration, but no difference in after atorvastatin.

These findings suggest that ECs have gut resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut diversity in PWH.

03

The Bottom Line · Clinical Pearl

“These findings suggest that ECs have gut microbiota resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut microbiota diversity in PWH.”

Published in The Journal of Infectious Diseases · Current Stage: Clinical Practice

Practical Next Step

Questions for Your Next Doctor Visit

  1. 1Based on my health history, do these infectious disease findings (standard-of-care clinical practice · Clinical evidence review in infectious disease care) apply to my situation?
  2. 2How do the potential benefits of this approach compare with the standard care I'm currently using?
  3. 3Given the study's key limitation (benefits and risks vary by individual health history — discuss with a healthcare professional.), what risks or follow-up steps should we watch for?
Infectious Disease · Clinical Practice
Study Type
Clinical evidence review

Standard-of-care clinical practice · Clinical evidence review

Evidence Score
3/5 · Real-World Observation
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Who It Applies To
Standard-of-care clinical practice · Clinical evidence review in infectious disease care
Intervention & Mechanism
Evaluation of gut microbiota composition in elite controllers and

Immune response

Key Limitation
Benefits and risks vary by individual health history — discuss with a healthcare professional.

Translational Stage

LEVEL 1 · Clinical Practice

Classified as Clinical evidence review along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. Human Evidence
  4. 4Clinical PracticeActive

Indexed Clinical Entities

Statins & Lipid-Lowering TherapyLong-Acting Antivirals & PrEPGut Microbiome & Mucosal Metabolites

Original Publication & AMA Citation

Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration. The Journal of Infectious Diseases. Published 2026;Oct 9. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42853985/

The Journal of Infectious Diseases

https://pubmed.ncbi.nlm.nih.gov/42853985/

Read Original Paper

Continue Reading

Related in Infectious Disease

View all Infectious Disease briefings →
INFECTIOUS DISEASE · CLINICAL PRACTICE

New International Guidelines Advance Phage Therapy for Superbugs

Personalized phage therapy, now backed by international guidelines, is becoming a viable and effective strategy against challenging multidrug-resistant bacterial infections. With antibiotic resistance posing a critical global health threat, these guidelines offer a vital new tool for clinicians.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDaily
INFECTIOUS DISEASE · PRECLINICAL

Successful archetype JC polyomavirus infection in hiPSC-derived neural culture of astrocytes and neurons

Our neural cell model reproduced many observations from PML brain tissue, suggesting that the model is appropriate to study key cellular events and the pathogenesis of JCPyV in neurodegeneration. JC polyomavirus (JCPyV) is the causative agent of progressive multifocal leukoencephalopathy (PML), a fatal neurodegenerative disease in immunocompromised individuals.

2/5 Preclinical
Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readThe Journal of Infectious Diseases
INFECTIOUS DISEASE · REAL-WORLD COHORT

Magnitude and durability of RSV-specific immune responses three years after hospitalization for RSV-associated acute respiratory illness among adults ≥50 years

RSV binding and neutralizing antibodies were transiently elevated following natural infection in older adults but waned to levels similar to RSV-negative participants by the next season's start. Vaccines that counter waning immunity are needed in this high-risk population.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious Diseases